Nuclea Biotech Buying Wilex's US Subsidiary | GenomeWeb

NEW YORK (GenomeWeb News) – Nuclea Biotechnologies and Wilex AG today announced an agreement for Nuclea to purchase Wilex Inc., a wholly owned subsidiary of Wilex AG.

Under the terms of the deal, Nuclea is purchasing all the shares of Wilex Inc. In addition to assuming all of the company's assets, Nuclea assumes responsibility for repayment of a $2.5 million loan between Wilex Inc. and Wilex AG.

Wilex AG is also eligible for single-digit royalties on net sales of Wilex Inc.'s HER2/neu and carbonic anhydrase IX, or CAIX, assays.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.